US2008145514A1PendingUtilityA1

Compositions and methods for coating medical implants

64
Assignee: ANGIOTECH INT AGPriority: May 24, 2002Filed: Jul 31, 2007Published: Jun 19, 2008
Est. expiryMay 24, 2022(expired)· nominal 20-yr term from priority
Inventors:William L. HunterDavid GravettPhilip M. ToleikisRichard LigginsTroy Loss
A61L 27/54A61P 31/00A61L 2300/416A61L 29/085A61P 43/00A61L 2300/404A61L 29/16A61L 27/34
64
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Medical implants are provided which release an anthracycline, fluoropyrimidine, folic acid antagonist, podophylotoxin, camptothecin, hydroxyurea, and/or platinum complex, thereby inhibiting or reducing the incidence of infection associated with the implant.

Claims

exact text as granted — not AI-modified
1 .- 23 . (canceled) 
     
     
         24 . A medical implant which comprises a fluoropyrimidine or a composition that comprises fluoropyridimine, wherein the fluoropyrimidine is in an amount effective to reduce or inhibit infection associated with the medical implant, wherein the medical implant is a pump, a venous port, a chronic infusion port, a vascular graft, a cardiac pacemaker, an implantable cardioverter defibrillator, an orthopedic implant, a urological implant, a prosthetic heart valve, an ocular implant, an ear, nose, or throat implant, a cardiac pacemaker lead, a neurological or neurosurgical device, a gastrointestinal device, a genitourinary device, an opthalmological implant, a plastic surgery implant, or a catheter cuff. 
     
     
         25 . The medical implant according to  claim 24 , wherein said implant is covered or coated in whole or in part with the composition comprising the fluoropyrimidine. 
     
     
         26 . The medical implant according to  claim 24 , wherein the fluoropyrimidine is 5-fluorouracil. 
     
     
         27 . The medical implant according to  claim 24 , wherein the implant comprises 1.0 μg to 250 mg fluoropyrimidine. 
     
     
         28 . The medical implant according to  claim 27 , wherein the implant comprises 10 μg to 25 mg fluoropyrimidine. 
     
     
         29 . The medical implant according to  claim 24 , wherein the implant comprises 0.1 μg to 1 mg fluoropyrimidine per mm 2  of surface area of the portion of the medical implant to which the fluoropyrimidine is applied or incorporated. 
     
     
         30 . The medical implant according to  claim 29 , wherein the implant comprises 1 μg to 50 μg fluoropyrimidine per mm 2  of surface area of the portion of the medical implant to which the fluoropyrimidine is applied or incorporated. 
     
     
         31 . The medical implant according to  claim 24 , wherein the fluoropyrimidine is present in an amount effective to reduce or inhibit bacterial infection associated with the medical implant. 
     
     
         32 . The medical implant according to  claim 31 , wherein the bacterial infection is antibiotic resistant. 
     
     
         33 . The medical implant according to  claim 24 , wherein the fluoropyrimidine is present in an amount effective to reduce or inhibit bacterial colonization of the medical implant. 
     
     
         34 . The medical implant according to  claim 24 , wherein the composition further comprises one or more polymers. 
     
     
         35 . The medical implant according to  claim 34 , wherein said composition comprises a non-biodegradable polymer. 
     
     
         36 . The medical implant according to  claim 35 , wherein the non-biodegradable polymer is selected from polyurethanes, acrylic or methacrylic copolymers, cellulose or cellulose-derived polymers, and blends thereof. 
     
     
         37 . The medical implant according to  claim 36 , wherein the polyurethane is a poly(carbonate urethane), poly(ester urethane) or poly(ether urethane). 
     
     
         38 . The medical implant according to  claim 36 , wherein the cellulose-derived cellulose is selected from nitrocellulose, cellulose acetate butyrate, and cellulose acetate propionate. 
     
     
         39 . The medical implant according to  claim 36 , wherein the implant comprises polyurethane and nitrocellulose. 
     
     
         40 . The medical implant according to  claim 24 , wherein the medical implant is a pump. 
     
     
         41 . The medical implant according to  claim 24 , wherein the medical implant is a venous port or a chronic infusion port. 
     
     
         42 . The medical implant according to  claim 24 , wherein the medical implant is a vascular graft. 
     
     
         43 . The medical implant according to  claim 24 , wherein the medical implant is a cardiac pacemaker. 
     
     
         44 . The medical implant according to  claim 24 , wherein the medical implant is an implantable cardioverter defibrillator. 
     
     
         45 . The medical implant of  claim 24 , wherein the medical implant further comprises a second anti-infective agent. 
     
     
         46 . The medical implant of  claim 45 , wherein the second anti-infective agent is an antibiotic. 
     
     
         47 . The medical implant of  claim 45 , wherein the second anti-infective agent is an antifungal agent. 
     
     
         48 . The medical implant of  claim 24 , wherein the medical implant further comprise an antithrombotic agent or an antiplatelet agent. 
     
     
         49 . The medical implant of  claim 48 , wherein the antithrombotic agent or the antiplatelet agent is selected from heparin, dextran sulphate, danaparoid, lepirudin, hirudin, AMP, adenosine, 2-chloroadenosine, aspirin, phenylbutazone, indomethacin, meclofenamate, hydrochloroquine, dipyridamole, iloprost, ticlopidine, clopidogrel, abcixamab, eptifibatide, tirofiban, streptokinase, and/or tissue plasminogen activator. 
     
     
         50 . The medical implant of  claim 24 , wherein the implant is coated with a composition comprising polyurethane, nitrocellulose and 5-fluorouracil in an amount of 0.1 μg to 1 mg per mm 2  of surface area of the portion of the implant to which 5-fluorouracil is applied or incorporated, wherein the implant releases 5-fluorouracil in an amount effective to reduce or inhibit infection associated with the implant. 
     
     
         51 . The medical device of  claim 50 , wherein the coating is on the exterior surface of the implant or a portion thereof. 
     
     
         52 . A method for making a medical implant, comprising covering, coating, combining, loading, associating, or impregnating a medical implant with a fluoropyrimidine or a composition that comprises a fluoropyrimidine in an amount effective to reduce or inhibit infection associated with the medical implant, wherein the medical implant is a pump, a venous port, a chronic infusion port, a vascular graft, a cardiac pacemaker, an implantable cardioverter defibrillator, an orthopedic implant, a urological implant, a prosthetic heart valve, an ocular implant, an ear, nose, or throat implant, a cardiac pacemaker lead, a neurological or neurosurgical device, a gastrointestinal device, a genitourinary device, an opthalmological implant, a plastic surgery implant, or a catheter cuff. 
     
     
         53 . The method according to  claim 52  wherein said medical implant is coated by dipping or by impregnation. 
     
     
         54 . A method for reducing or inhibiting infection associated with a medical implant, comprising introducing into a patient the medical implant of  claim 24 . 
     
     
         55 . The method of  claim 54 , wherein the infection is bacterial infection. 
     
     
         56 . The method of  claim 54 , wherein the fluoropyrimidine is 5-fluorouracil.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.